Olmesartan functions as an angiotensin II receptor blocker (ARB). It works by inhibiting the binding of angiotensin II to the AT1 receptor, which is found in the smooth muscle of blood vessels. This blockade prevents angiotensin II from causing vasoconstriction, a narrowing of the blood vessels. By preventing vasoconstriction, olmesartan helps to relax blood vessels, leading to lower blood pressure.
What happens when olmesartan blocks angiotensin II?
When olmesartan blocks angiotensin II from binding to its AT1 receptor, several effects occur that contribute to lowering blood pressure. Angiotensin II normally constricts blood vessels and stimulates the release of aldosterone, a hormone that causes the body to retain sodium and water, both of which increase blood pressure. By blocking these actions, olmesartan causes vasodilation, reducing peripheral vascular resistance. It also reduces aldosterone secretion, leading to less sodium and water retention, further contributing to lower blood pressure.
How does olmesartan compare to other blood pressure medications?
As an ARB, olmesartan belongs to a class of drugs that target the renin-angiotensin-aldosterone system. Other classes of blood pressure medications work through different mechanisms. For example, ACE inhibitors also affect the renin-angiotensin-aldosterone system but by preventing the production of angiotensin II rather than blocking its receptor. Beta-blockers reduce heart rate and the force of heart contractions. Calcium channel blockers relax blood vessels by preventing calcium from entering smooth muscle cells. Diuretics help the body eliminate excess salt and water. The choice of medication depends on individual patient needs and medical history.
What is the typical dosage and administration of olmesartan?
Olmesartan is typically taken orally, once a day, with or without food. The usual starting dose for adults is 20 mg. Doses can be adjusted by a healthcare provider based on the patient's response and tolerance, with typical maintenance doses ranging from 20 mg to 40 mg daily.
What are the common side effects associated with olmesartan?
Common side effects of olmesartan can include dizziness, lightheadedness, and occasional fainting, especially when starting the medication or increasing the dose. Other reported side effects may include diarrhea, headache, and upper respiratory tract infections.
Are there any serious risks or contraindications for olmesartan use?
Serious risks associated with olmesartan include angioedema, a severe allergic reaction causing swelling of the face, lips, tongue, or throat, which can be life-threatening. It is also associated with fetal toxicity, meaning it can cause injury or death to a developing fetus, and should not be used during pregnancy. Patients with a history of hypersensitivity to olmesartan or any of its components should not take the medication.
When does the patent for olmesartan expire?
Information on patent expiry for olmesartan can be found through resources that track drug patents. According to DrugPatentWatch.com, patent expiry dates can vary based on specific patents and jurisdictions [1]. Generally, once patents expire, generic versions of the drug can become available.
Can generic versions of olmesartan be made before patent expiration?
Generic versions of olmesartan cannot legally be manufactured and marketed until the relevant patents have expired and any applicable exclusivity periods have ended. This ensures that the innovator company has a period of market exclusivity to recoup its research and development costs.
How does olmesartan work at a molecular level?
At a molecular level, olmesartan is a selective antagonist of the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor and also stimulates aldosterone release. By competitively binding to the AT1 receptor, olmesartan prevents angiotensin II from activating this receptor and initiating the downstream signaling pathways that lead to vasoconstriction and aldosterone release. This blockade effectively interrupts the renin-angiotensin-aldosterone system's contribution to elevated blood pressure.
---
Sources
1. DrugPatentWatch.com